Search

Displaying results 1691 - 1700 of 4588 in total
  1. Drug

    Reserpine

    go.drugbank.com/drugs/DB00206
    ApprovedWithdrawn

    It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.

  2. Drug

    Vidarabine

    go.drugbank.com/drugs/DB00194
    ApprovedWithdrawn

    It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the

  3. Drug

    Indalpine

    go.drugbank.com/drugs/DB08953
    ApprovedWithdrawn

    It was initially marketed by Pharmuka. … However, after the emergence of widespread concern regarding adverse effects caused by SSRIs, and reported hematological effects caused by Indalpine, it was abruptly withdrawn from the US market.

  4. Drug

    Difamilast

    go.drugbank.com/drugs/DB14987
    ApprovedInvestigational

    Atopic dermatitis is a chronic and fluctuating pruritic inflammatory skin condition characterized by pruritic eczema and is also marked by exacerbations and remissions.

  5. Drug

    Lorazepam

    go.drugbank.com/drugs/DB00186
    ApprovedInvestigational

    [A957] It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. … The first historic FDA label approval is reported in 1985 by the company Mutual Pharm.[L5095]

  6. Drug

    mRNA-1345

    go.drugbank.com/drugs/DB18739
    ApprovedInvestigational

    mRNA-1345 is a nucleoside modified mRNA encoding the F-glycoprotein from RSV subtype A stabilized in its prefusion conformation. It is the primary ingredient of the RSV vaccine mRESVIA. mRESVIA was first approved in the EU and US in 2024...

  7. Drug

    Safrazine

    go.drugbank.com/drugs/DB09253
    ApprovedWithdrawn

    In 1960, it was used as an antidepressant but it is now discontinued.

  8. Drug

    Lixisenatide

    go.drugbank.com/drugs/DB09265
    ApprovedInvestigational

    It is sold by Sanofi-Aventis under the brand name Adlyxin in the US[L763] and Lyxumia in the EU.[L764] Adlyxin recieved FDA approval July 28, 2016.[L763]

  9. Drug

    Pralsetinib

    go.drugbank.com/drugs/DB15822
    ApprovedInvestigational

    It is currently marketed under the brand name GAVRETO™ by Blueprint Medicines.[L15986]

  10. Drug

    Methfuroxam

    go.drugbank.com/drugs/DB16231
    Investigational

    Methfuroxam is under investigation in clinical trial NCT01213407 (Dendritic Cell Cancer Vaccine for High-grade Glioma).